“The revised rating reflects limited operating flexibility as management moves into and operationalizes its new patient tower in fiscal [year] 2017, and as SARH adds new costs to its operating base which may take a couple of years to stabilize given the size and scale of the project,” said S&P analyst Aamna Shah.
The outlook is stable.
More articles on healthcare finance:
For-profit hospital stock report: Week of Dec. 5-9
Zirmed named to Built In Chicago 2016 Top 100 Digital Companies list
Moody’s revises Vidant Health’s outlook to stable
